BerandaNZYMB • SWX
add
Novozymes A/S
Tutup sebelumnya
CHF 44,68
Rentang tahun
CHF 44,68 - CHF 44,68
Kapitalisasi pasar
169,71 M DKK
Rasio P/E
-
Hasil dividen
-
Bursa utama
CPH
Berita pasar
Keuangan
Laporan Pendapatan
Pendapatan
Laba bersih
| (EUR) | Jun 2024info | Perubahan Y/Y |
|---|---|---|
Pendapatan | 915,85 jt | 61,70% |
Biaya operasional | 271,75 jt | 52,62% |
Laba bersih | 31,95 jt | -60,72% |
Margin laba bersih | 3,49 | -75,70% |
Penghasilan per saham | — | — |
EBITDA | 150,94 jt | -16,50% |
Tarif pajak efektif | 29,00% | — |
Neraca
Total aset
Total liabilitas
| (EUR) | Jun 2024info | Perubahan Y/Y |
|---|---|---|
Investasi tunai jangka pdk | 260,80 jt | 85,35% |
Total aset | 15,25 M | 302,43% |
Total liabilitas | 4,25 M | 119,23% |
Total ekuitas | 11,00 M | — |
Saham yang beredar | 277,90 jt | — |
Harga terhadap nilai buku | 1,13 | — |
Tingkat pengembalian aset | 1,83% | — |
Tingkat pengembalian modal | 2,15% | — |
Arus Kas
Perubahan kas bersih
| (EUR) | Jun 2024info | Perubahan Y/Y |
|---|---|---|
Laba bersih | 31,95 jt | -60,72% |
Kas dari operasi | 264,05 jt | 74,01% |
Kas dari investasi | -27,45 jt | 70,98% |
Kas dari pembiayaan | -186,70 jt | -205,10% |
Perubahan kas bersih | 55,55 jt | 902,56% |
Arus kas bebas | -17,57 jt | 68,87% |
Tentang
Novozymes A/S was a global biotechnology company headquartered in Bagsværd, outside of Copenhagen, Denmark. The company's focus was the research, development and production of industrial enzymes, microorganisms, and biopharmaceutical ingredients. The company merged with Chr. Hansen to form Novonesis in January 2024.
Prior to the merger, the company had operations around the world, including in China, India, Brazil, Argentina, United Kingdom, the United States, and Canada. Class B shares of its stock were listed on the NASDAQ OMX Nordic exchange. Wikipedia
CEO
Didirikan
2000
Situs
Karyawan
10.452
